.Pharmacolibrary.Drugs.ATC.G.G04BD07

Information

Tolterodine is a competitive muscarinic receptor antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. It is approved and widely used today as a symptomatic treatment for overactive bladder.

Pharmacokinetics

Pharmacokinetic parameters reported for healthy adult volunteers after single oral administration of tolterodine immediate release formulation.

References

1. Olsson, B, & Landgren, BM (2001). The effect of tolterodine on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Clinical therapeutics 23(11) 1876–1888. DOI:10.1016/s0149-2918(00)89083-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11768839

2. Oishi, M, et al., & Malhotra, B (2014). Population pharmacokinetics of the 5-hydroxymethyl metabolite of tolterodine after administration of fesoterodine sustained release tablet in Western and East Asian populations. Journal of clinical pharmacology 54(8) 928–936. DOI:10.1002/jcph.274 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24619889

3. Guay, DR (2003). Clinical pharmacokinetics of drugs used to treat urge incontinence. Clinical pharmacokinetics 42(14) 1243–1285. DOI:10.2165/00003088-200342140-00004 PUBMED:https://pubmed.ncbi.nlm.nih.gov/14606931

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)